Cullinan Oncology, Inc.

NASDAQ (USD): Cullinan Oncology, Inc. (CGEM)

Last Price

16.81

Today's Change

-2.21 (11.61%)

Day's Change

16.78 - 18.92

Trading Volume

1,320,716

Profile
CGEM

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Nadim Ahmed Mr. Nadim Ahmed

Full Time Employees:  85 85

IPO Date:  2021-01-08 2021-01-08

CIK:  0001789972 0001789972

ISIN:  US2300311063 US2300311063

CUSIP:  230031106 230031106

Beta:  -0.06 -0.06

Last Dividend:  0.00 0.00

Dcf Diff:  14.53 14.53

Dcf:  2.28 2.28

Description

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Address

One Main Street,
Cambridge, MA 02142, US

617 410 4650

http://www.cullinanoncology.com

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment